Nautilus Biotechnology will report Q3 2026 financial results on October 27, followed by a management webcast.
Quiver AI Summary
Nautilus Biotechnology, Inc. announced that it will release its financial results for the third quarter of 2026 on October 27, 2026, before market opening. The company's management will host a conference call to discuss the results, business developments, and future outlook, starting at 5:30 a.m. Pacific Time. Interested parties can access the live audio webcast on the company's website. Nautilus, headquartered in Seattle, is focused on developing a platform technology for protein analysis to enhance understanding of the proteome and advance health and medicine.
Potential Positives
- Nautilus will report its third quarter 2026 financial results, indicating ongoing corporate activity and transparency with stakeholders.
- The scheduled conference call reflects the company's commitment to engaging with investors and the broader market about its business developments and outlook.
Potential Negatives
- The company did not provide details on expected financial performance, which may raise concerns among investors about transparency and preparedness.
- As a development stage company, Nautilus Biotechnology may face skepticism regarding its ability to deliver on its mission and commercialize its technology effectively.
- Announcing the financial results after market open could lead to volatile trading if the results are below market expectations.
FAQ
When will Nautilus Biotechnology report Q3 2026 financial results?
Nautilus Biotechnology will report its third quarter 2026 financial results on October 27, 2026, before market open.
What time is the Nautilus conference call?
The conference call will begin at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
Where can I access Nautilus' webcast?
The live audio webcast can be accessed in the “Investors” section of Nautilus' website at www.nautilus.bio.
What does Nautilus Biotechnology specialize in?
Nautilus specializes in single-molecule protein analysis and aims to transform the field of proteomics.
How can I contact Nautilus for media inquiries?
Media inquiries can be directed to [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NAUT Insider Trading Activity
$NAUT insiders have traded $NAUT stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $NAUT stock by insiders over the last 6 months:
- EQUITY PARTNERS BIO II, L.L.C. AH has made 0 purchases and 2 sales selling 5,000,000 shares for an estimated $11,750,000.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NAUT Hedge Fund Activity
We have seen 56 institutional investors add shares of $NAUT stock to their portfolio, and 30 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- A16Z CAPITAL MANAGEMENT, L.L.C. removed 8,590,863 shares (-48.7%) from their portfolio in Q2 2026, for an estimated $16,064,913
- BLACKROCK, INC. added 2,499,555 shares (+1331.9%) to their portfolio in Q2 2026, for an estimated $4,674,167
- AMAZON COM INC removed 1,457,055 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $2,724,692
- CLEARSTEAD ADVISORS, LLC removed 1,436,997 shares (-61.7%) from their portfolio in Q2 2026, for an estimated $2,687,184
- MILLENNIUM MANAGEMENT LLC removed 1,084,653 shares (-85.2%) from their portfolio in Q2 2026, for an estimated $2,028,301
- PERCEPTIVE ADVISORS LLC removed 960,000 shares (-7.6%) from their portfolio in Q2 2026, for an estimated $1,795,200
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 890,949 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,666,074
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2026 before market open on Tuesday, October 27, 2026.
The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio .
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit
www.nautilus.bio
.
Media Contact
[email protected]
Investor Contact
[email protected]
